Q4 2025 Veru Inc Earnings Call Transcript
Key Points
- Veru Inc (VERU) reported positive results from its phase 2B clinical trial for Enovosarm, demonstrating 100% preservation of lean mass and a 12% greater fat loss compared to placebo.
- The company received FDA regulatory clarity to advance the clinical development of Enovosarm in combination with GLP-1 receptor agonists.
- Veru Inc (VERU) completed a public offering, resulting in net proceeds of approximately $23.4 million, strengthening its financial position.
- The company has a robust intellectual property portfolio, with patents extending to 2043 and a new formulation patent extending to 2046.
- Veru Inc (VERU) successfully transitioned its focus exclusively to drug development by selling its FC2 female condom business, allowing for a more streamlined operational strategy.
- Veru Inc (VERU) reported a net loss of $15.7 million from continuing operations for the fiscal year, indicating ongoing financial challenges.
- The company experienced a decrease in cash and cash equivalents, with a balance of $15.8 million as of September 30, 2025, compared to $24.9 million the previous year.
- Research and development costs increased to $15.6 million, reflecting higher expenses related to clinical studies.
- The sale of the FC2 female condom business resulted in a loss of approximately $4.1 million, impacting overall financial performance.
- Veru Inc (VERU) is not yet profitable and will require additional capital to support its drug development candidates, highlighting the need for continued financial management.
Good morning ladies and gentlemen, and welcome to Veru Inc.s investors conference call.
All participants will be in a listen-only mode.
Should you need assistance, please signal a conference specialist by pressing the key, followed by 0.
After this morning's discussion, there will be an opportunity to ask.
Questions.
Please note that this event is being recorded.
I would now like to turn the conference call over to Mr. SAM Fish, Baru Inc.s executive director, Investor relations and corporate communications. Please go ahead.
The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations, or intentions regarding its business operations, regulatory interactions, finances, and development of product portfolio.
Such forward-looking statements are subject to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
